Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

LLY – Eli Lilly and Company

Eli Lilly and Company
LLY
$775.45
Name : Eli Lilly and Company
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $696,149,409,792.00
EPSttm : 12.25
finviz dynamic chart for LLY
Eli Lilly and Company
$775.45
2.47%
$19.67

Float Short %

0.94

Margin Of Safety %

Put/Call OI Ratio

0.73

EPS Next Q Diff

2.77

EPS Last/This Y

10.02

EPS This/Next Y

7.83

Price

775.59

Target Price

987.22

Analyst Recom

1.52

Performance Q

-5.63

Relative Volume

0.99

Beta

0.4

Ticker: LLY




19 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-06-02LLY745.950.510.56452201
2025-06-03LLY751.280.510.55463980
2025-06-04LLY765.840.520.59468709
2025-06-05LLY765.650.530.46472863
2025-06-06LLY769.660.550.47473667
2025-06-09LLY773.680.530.89453613
2025-06-10LLY807.30.540.69460011
2025-06-11LLY808.750.550.61470927
2025-06-12LLY8120.560.23476083
2025-06-13LLY819.290.550.51486186
2025-06-16LLY807.650.550.89457883
2025-06-17LLY791.590.560.68466846
2025-06-18LLY784.80.561.67474803
2025-06-20LLY761.780.570.76480828
2025-06-23LLY770.40.710.75341761
2025-06-24LLY778.790.720.57355093
2025-06-25LLY7930.720.70365986
2025-06-26LLY795.110.730.83373440
2025-06-27LLY773.510.730.85378498
DateSymbolLastP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-06-02LLY747.0341.19928.821.78
2025-06-03LLY750.7841.19751.021.78
2025-06-04LLY766.3841.110114.421.78
2025-06-05LLY765.6841.49634.121.79
2025-06-06LLY769.9541.79751.521.79
2025-06-09LLY773.7141.79737.821.79
2025-06-10LLY807.4641.710623.021.79
2025-06-11LLY808.8541.79671.121.79
2025-06-12LLY812.0341.79721.021.79
2025-06-13LLY819.5641.79836.721.78
2025-06-16LLY807.7341.79297.821.78
2025-06-17LLY791.3241.79161.721.78
2025-06-18LLY785.0341.79443.921.78
2025-06-20LLY762.7341.78972.821.78
2025-06-23LLY770.4241.79854.721.78
2025-06-24LLY779.0541.79873.821.78
2025-06-25LLY792.54- 10049.70.00
2025-06-26LLY795.1141.79698.321.78
2025-06-27LLY775.5941.79060.621.78
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-06-02LLY-0.890.510.86
2025-06-03LLY-0.890.510.86
2025-06-04LLY-0.890.510.86
2025-06-05LLY-0.890.510.86
2025-06-06LLY-0.890.510.86
2025-06-09LLY-0.890.500.86
2025-06-10LLY-0.890.500.86
2025-06-11LLY-0.890.500.94
2025-06-12LLY-0.890.500.94
2025-06-13LLY-0.890.500.94
2025-06-16LLY-0.890.800.94
2025-06-17LLY-0.890.800.94
2025-06-18LLY-0.890.800.94
2025-06-20LLY-0.890.800.94
2025-06-23LLY-0.890.740.94
2025-06-24LLY-0.890.740.94
2025-06-25LLY-0.890.740.94
2025-06-26LLY-0.890.740.94
2025-06-27LLY-0.890.740.94
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

3.34

Avg. EPS Est. Current Quarter

5.55

Avg. EPS Est. Next Quarter

6.11

Insider Transactions

-0.89

Institutional Transactions

0.74

Beta

0.4

Average Sales Estimate Current Quarter

14372

Average Sales Estimate Next Quarter

15359

Fair Value

Quality Score

95

Growth Score

100

Sentiment Score

92

Actual DrawDown %

20.3

Max Drawdown 5-Year %

-25.3

Target Price

987.22

P/E

64.24

Forward P/E

26.14

PEG

1.55

P/S

15

P/B

46.64

P/Free Cash Flow

196.69

EPS

12.07

Average EPS Est. Cur. Y​

21.78

EPS Next Y. (Est.)

29.61

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

22.66

Relative Volume

0.99

Return on Equity vs Sector %

46.5

Return on Equity vs Industry %

38.3

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.02

EBIT Estimation

9060.6
Eli Lilly and Company
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 47000
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
stock quote shares LLY – Eli Lilly and Company Stock Price stock today
news today LLY – Eli Lilly and Company stock forecast ,stock prediction 2023 2024 2025
marketwatch LLY – Eli Lilly and Company yahoo finance google finance
stock history LLY – Eli Lilly and Company invest stock market
stock prices LLY premarket after hours
ticker LLY fair value insiders trading